A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Phase 2 Completed 184 enrolled Avid Radiopharmaceuticals

Non-randomizedSingle-groupSingle-blindDiagnostic

Summary

Evaluate 18F-AV-45 positron emission tomography (PET) imaging for distinguishing healthy control subjects, from subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).

Timeline

Start: 2008-06
Primary completion: 2008-12
Completion: 2008-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	florbetapir F 18	Diagnostic / imaging agent	370 mbq	Intravenous

A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Summary

Timeline

Drugs

Indications